— HUTCHMED’s fourth product, and its first approval in hematological malignancies — HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ...

Reports revenue $630.2M vs. $838M last year. an Eldar, Non-executive Chairman of HUTCHMED (HCM), said, “The successful commercialization of FRUZAQLA outside of China by our partner Takeda and ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (HKEX: 13 ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM: HCM; HKEX: 13) today announces that the New Drug ...

Hong Kong, Shanghai & Florham Park, NJ — Wednesday, March 19, 2025: HUTCHMED (China) Limited (“HUTCHMED”, the “Company” or “we”) (HKEX: 13; Nasdaq/AIM: HCM) today reports its financial results for the ...

HONG KONG - Hutchmed (China) Limited (NASDAQ/AIM:HCM, HKEX:13), a biopharmaceutical company, today disclosed the upcoming retirement of two of its Independent Non-executive Directors, Mr Paul ...

HONG KONG - Hutchmed (China) Limited (NASDAQ/AIM: HCM; HKEX: 13), a commercial-stage biopharmaceutical company, announced today that its shareholders passed an ordinary resolution during an ...

Despite reporting lower-than-expected revenue for 2024, Hutchmed (NASDAQ:HCM) traded higher on Wednesday after the Chinese biotech announced that a Phase 2/3 trial for its cancer drug combo ...

Hutchmed reported 2024 earnings of $0.22 per ADS, down from $0.71 last year, with sales falling 25% to $630.2 million. FRUSICA-2 trial met its primary endpoint, supporting fruquintinib’s use in ...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited ("HUTCHMED”, the "Company” or "we”) (HKEX: 13; Nasdaq/AIM: HCM) today reports its financial ...